Skip to main content
OpenTrials

Clinical trial condition

Primary Immunodeficiency Diseases

Explore clinical trials studying Primary Immunodeficiency Diseases. Study availability and eligibility vary by location and protocol.

161 public trials 33 recruiting studies
Refine in advanced search Browse all conditions

Primary Immunodeficiency Diseases trial results

Completed

An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease

NCT04842643

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • Nagoya University Hospital Nagoya, Aichi-ken, Japan
  • Kurume University Hospital Kurume, Fukuoka, Japan
  • Kanazawa University Hospital Kanazawa, Ishikawa-ken, Japan
  • National defense medical college Hospital Tokorozawa, Saitama, Japan
View Trial Details
Completed

A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID)

NCT05150340

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • Nagoya University Hospital Nagoya, Aichi-ken, Japan
  • Hospital of University of Occupational and Environmental Health Kitakyushu, Fukuoka, Japan
  • Kurume University Hospital Kurume, Fukuoka, Japan
  • Kanagawa Children's Medical Center Yokohama, Kanagawa, Japan
View Trial Details
Completed

A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)

NCT04346108

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • Nagoya University Hospital Nagoya, Aichi-ken, Japan
  • Kyushu University Hospital Fukuoka, Japan
  • Kurume University Hospital Kurume-shi, Fukuoka, Japan
  • Gifu University Hospital Gifu, Japan
View Trial Details
Completed

Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases

NCT03939533

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • Octapharma Research Site Scottsdale, Arizona, United States
  • Octapharma Research Site Irvine, California, United States
  • Octapharma Research Site Santa Barbara, California, United States
  • Octapharma Research Site Centennial, Colorado, United States
View all 18 locations
View Trial Details
Completed

Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects

NCT03277313

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • University of Alabama Medical Center Birmingham, Alabama, United States
  • Connecticut Children's Medical Center Hartford, Connecticut, United States
  • University of Miami Pediatric Allergy and Immunology Miami, Florida, United States
  • University of South Florida Physician Group St. Petersburg, Florida, United States
View all 19 locations
View Trial Details
Completed

A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency

NCT04566692

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • Clinical Research Center of Alabama Birmingham, Alabama, United States
  • Research Solutions of Arizona, PC Litchfield Park, Arizona, United States
  • Allergy Associates of The Palm Beaches North Palm Beach, Florida, United States
  • Allergy & Asthma Clinics of Georgia, P.C. Albany, Georgia, United States
View Trial Details
Completed

Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID

NCT02810444

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • Investigational site # 0104 Birmingham, Alabama, United States
  • Investigational site # 0116 Los Angeles, California, United States
  • Investigational site # 0103 Centennial, Colorado, United States
  • Investigational site # 0114 Thornton, Colorado, United States
View all 19 locations
View Trial Details

Related conditions